| Name | Title | Contact Details |
|---|---|---|
Dylan Nowakowski |
Assistant Director of Financial Aid | Profile |
We at Kerkman & Dunn are dedicated to our clients, we will fight for you. Contact us at 414-278-7000 or fill out our online contact form today.
Harvey Performance Company, established in 1985 and based in Rowley, Massachusetts, is a prominent designer and manufacturer of specialty carbide cutting tools for precision machining. The company operates under five brands: Harvey Tool, Helical Solutions, Micro 100, Titan USA, and CoreHog, with additional facilities in Gorham, Maine; Meridian, Idaho; and West Springfield, Massachusetts. With a workforce of around 350 employees, it is led by President and CEO Peter Jenkins. The company specializes in high-performance cutting tools, including micro-tools, end mills, and custom tooling solutions, tailored for industries such as aerospace, medical devices, electronics, telecommunications, and general machining. Harvey Performance is known for its fast service, comprehensive product support, and technical expertise, catering to manufacturers that require extreme precision and tight tolerances. The company also actively participates in community initiatives and workforce development, supporting local technical schools and charitable events.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
IDB Bank is an American multinational private and commercial bank headquartered in New York City. It operates in the United States, Latin America, and Israel, and is chartered by the State of New York. As a member of the Federal Deposit Insurance Corporation (FDIC), IDB Bank provides a range of financial services. The bank offers personal banking services, including checking and savings accounts, credit cards, personal loans, and mortgages. For businesses, it provides commercial loans, lines of credit, cash management services, and business checking accounts. Additionally, IDB Bank offers investment products and wealth management services, catering to both individual and business financial needs. With a history dating back to 1949, IDB Bank has evolved from a representative office to a full-service bank, reflecting its commitment to serving a diverse client base across its operational regions.